Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosmetpantotenate in PKAN
2016-001955-29Phase 3Completed
- Sponsor
- Travere Therapeutics
- Start
- Mar 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosmetpantotenate in pantothenate kinase-associated neurodegeneration (PKAN) (3 arms), sponsored by Travere Therapeutics. Primary endpoint: Primary Efficacy Endpoint. Started Mar 2017; status: completed.
02
Drugs
fosmetpantotenate
03
Conditions
pantothenate kinase-associated neurodegeneration (PKAN)
Beyond the preview
Go deeper on 2016-001955-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001955-29.